Skip to main content

Advertisement

SpringerLink
Log in

Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy

  • AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shelburne 3rd SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Med (Baltimore). 2002;81:213–27.

    Article  Google Scholar 

  2. Casanova Estruch B. Safety profile and practical considerations of monoclonal antibody treatment. Neurologia. 2013;28(3):169–78. Safety profile and practical considerations of monoclonal antibody treatment.

    Article  CAS  PubMed  Google Scholar 

  3. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85–92.

    Article  CAS  PubMed  Google Scholar 

  4. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40(12):1756–61.

    Article  CAS  PubMed  Google Scholar 

  5. Cadena J, Thompson III GR, Ho TT, Medina E, Hughes DW, Patterson TF. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia. Diagn Microbiol Infect Dis. 2009;64(3):327–30.

    Article  PubMed  Google Scholar 

  6. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, Rodriguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40(5):756–9.

    Article  PubMed  Google Scholar 

  7. Melboucy-Belkhir S, Flexor G, Stirnemann J, Morin AS, Boukari L, Polliand C, et al. Prolonged paradoxical response to anti-tuberculous treatment after infliximab. Int J Infect Dis. 2010;14:e333–4.

    Article  PubMed  Google Scholar 

  8. Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59(8):704–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohn’s Colitis. 2014;8(6):550–7.

    Article  Google Scholar 

  10. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol. 2012;10(2):150–6. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Sun HY, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis. 2009;22(4):394–402.

    Article  CAS  PubMed  Google Scholar 

  12. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.

    Article  PubMed  Google Scholar 

  13. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.

    Article  PubMed  Google Scholar 

  14. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369(2):197–8.

    Article  CAS  PubMed  Google Scholar 

  15. Lima MA. Progressive multifocal leukoencephalopathy: new concepts. Arq Neuropsiquiatr. 2013;71(9B):699–702. Progressive Multifocal leukoencephalopathy: new concepts.

    Article  PubMed  Google Scholar 

  16. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013;19(14):1826–40.

    Article  CAS  PubMed  Google Scholar 

  17. Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 2013;81(16):1400–8.

    Article  CAS  PubMed  Google Scholar 

  18. Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med. 2011;78 Suppl 2:S33–7. Advances in the management of PML: Focus on natalizumab.

    Article  PubMed  Google Scholar 

  19. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 2012;123(2):235–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Schrōder A, De-Hyung L, Hellwig K, et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol. 2010;67(11):1391–4.

    PubMed  Google Scholar 

  22. Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2013;84:1068–74.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol. 2010;9(4):425–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Benkert TF, Dietz L, Hartmann EM, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One. 2012;7(12):e52208.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Fine AJ, Sorbello A, Kortepeter C, et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol. 2014;75:108–15. Progressive Multifocal Leukoencephalopathy after Natalizumab Discontinuation.

    Article  CAS  PubMed  Google Scholar 

  26. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012;71(7):604–17.

    Article  CAS  PubMed  Google Scholar 

  27. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–46.

    Article  CAS  PubMed  Google Scholar 

  28. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24(3):284–90.

    Article  CAS  PubMed  Google Scholar 

  29. Clifford DB. Progressive multifocal leukoencephalopathy therapy. J Neurovirol. 2014.

  30. Blinkenberg M, Sellebjerg F, Leffers AM, et al. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Mult Scler. 2013;19(9):1226–9.

    Article  PubMed  Google Scholar 

  31. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012;78(18):1390–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370(5):486–8.

    Article  CAS  PubMed  Google Scholar 

  33. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology. 2012;79(23):2258–64.

    Article  CAS  PubMed  Google Scholar 

  34. Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? J Neurol Neurosurg Psychiatry. 2013;84(10):1176–7.

    Article  PubMed  Google Scholar 

  35. Schwab N, Höhn KG, Schneider-Hohendorf T, et al. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler. 2012;18(3):335–44.

    Article  CAS  PubMed  Google Scholar 

  36. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8(10):601–11.

    Article  CAS  PubMed  Google Scholar 

  37. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001;69(3):1847–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561–72.

    Article  CAS  PubMed  Google Scholar 

  39. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168(9):4620–7.

    Article  CAS  PubMed  Google Scholar 

  40. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol. 2005;174(8):4852–9.

    Article  CAS  PubMed  Google Scholar 

  41. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162(6):3504–11.

    CAS  PubMed  Google Scholar 

  42. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  43. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis. 2005;41 Suppl 3:S189–93.

    Article  CAS  PubMed  Google Scholar 

  44. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.

    Article  CAS  PubMed  Google Scholar 

  45. Belkaid Y. Regulatory T, cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7(11):875–88.

    Article  CAS  PubMed  Google Scholar 

  46. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.

    Article  CAS  Google Scholar 

  47. Singh N. Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur J Clin Microbiol Infect Dis. 2008;27(6):403–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009;48(10):1429–32.

    Article  PubMed  Google Scholar 

  49. Rivoisy C, Amrouche L, Carcelain G, Sereni D, Bourgarit A. Paradoxical exacerbation of tuberculosis after TNFalpha antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine. 2011;78(3):312–5.

    Article  CAS  PubMed  Google Scholar 

  50. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis. 2005;9(9):1057–8.

    PubMed  Google Scholar 

  51. Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007;45(11):1470–5.

    Article  CAS  PubMed  Google Scholar 

  52. Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F. Life-threatening disseminated tuberculosis as a complication of TNF-alpha blockade in an adolescent. Eur J Pediatr. 2011;170(10):1337–42.

    Article  CAS  PubMed  Google Scholar 

  53. Yoon YK, Kim JY, Sohn JW, Kim MJ, Koo JS, Choi JH, et al. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report. J Med Case Rep. 2009;3:6673. Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–5.

    Article  CAS  PubMed  Google Scholar 

  55. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis. 2009;22(4):403–9.

    Article  CAS  PubMed  Google Scholar 

  56. Cheng VC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PC, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21(11):803–9.

    Article  CAS  PubMed  Google Scholar 

  57. Safdar A, Brown AE, Kraus DH, Malkin M. Paradoxical reaction syndrome complicating aural infection due to Mycobacterium tuberculosis during therapy. Clin Infect Dis. 2000;30(3):625–7.

    Article  CAS  PubMed  Google Scholar 

  58. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828–38.

    Article  CAS  PubMed  Google Scholar 

  59. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008;47(10):e83–5.

    Article  CAS  PubMed  Google Scholar 

  60. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis. 2005;41(2):201–8.

    Article  CAS  PubMed  Google Scholar 

  61. Broady R, Levings MK. Graft-versus-host disease: suppression by statins. Nat Med. 2008;14(11):1155–6.

    Article  CAS  PubMed  Google Scholar 

  62. Pateinakis P, Pyrpasopoulou A (2014) CD20+ B cell depletion in systemic autoimmune diseases: common mechanisms of inhibition or disease-specific effect on humoral immunity? Biomed Res Int.

  63. Van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63:1507–16.

    Article  PubMed  Google Scholar 

  64. Canaani J, Amit S, Ben-Ezra J, et al. Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma. J Clin Oncol. 2013;31(11):178–80.

    Article  Google Scholar 

  65. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;9(8):816–24.

    Article  Google Scholar 

  67. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Doheny K. FDA rejects MS drug Lemtrada, WebMD, 12/30/2013, http://www.webmd.com/multiple-sclerosis/news/20131230/fda-rejects-ms-drug-lemtrada.

  70. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44:e115–7.

    Article  PubMed  Google Scholar 

  71. Crossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;11(6):573–9.

    Article  Google Scholar 

  72. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:693–702. Immune Reconstitution Syndrome and the Thyroid.

    Article  CAS  PubMed  Google Scholar 

  73. Berger J. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33(11):969–83.

    Article  CAS  PubMed  Google Scholar 

  74. Kothary N, Diak I, Brinker A, Bezabeh S, Abigan M, Pan GD. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3):546–51.

    Article  CAS  PubMed  Google Scholar 

  75. Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorg T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy. Neurology. 2012;78:458–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–70. JAKs and STATs in immunity, immunodeficiency, and cancer.

    Article  PubMed  Google Scholar 

  77. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012;8:95–103.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–9.

    Article  PubMed  Google Scholar 

  79. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Takao M. Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies. Brain Nerve. 2013;65(11):1363–74.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Malika Gupta, Kashif Jafri, Rebecca Sharim, Susanna Silverman, Sayantani B. Sindher, Anupama Shahane, and Mildred Kwan declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Allergy and Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Malika Gupta & Sayantani B. Sindher

  2. Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Kashif Jafri

  3. Division of Rheumatology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Rebecca Sharim & Anupama Shahane

  4. Division of Pulmonary, Allergy, and Critical Care, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Susanna Silverman & Mildred Kwan

  5. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Malika Gupta, Kashif Jafri, Rebecca Sharim, Susanna Silverman, Sayantani B. Sindher, Anupama Shahane & Mildred Kwan

  6. 1001 Chesterbrook Blvd, Ste 300, Berwyn, PA, 19312, USA

    Mildred Kwan

Authors
  1. Malika Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kashif Jafri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca Sharim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susanna Silverman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sayantani B. Sindher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anupama Shahane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mildred Kwan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mildred Kwan.

Additional information

This article is part of the Topical Collection on Autoimmunity

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, M., Jafri, K., Sharim, R. et al. Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy. Curr Allergy Asthma Rep 15, 499 (2015). https://doi.org/10.1007/s11882-014-0499-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-014-0499-4

Keywords

Search

Navigation